Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia

Pradjatmo, Heru

doi:10.7314/apjcp.2015.16.18.8599

Cited by 7 publications

(4 citation statements)

References 22 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liu et al (2014) reported in their study found that adjuvant chemotherapy either. Previous researchers have reported that stage of the disease is a prognostic factor of survival in ovarian cancer patients (du Bois et al, 2009;Tang et al, 2012;Liu et al, 2014;Chen et al, 2015;Nassar et al, 2015;Pradjatmo, 2015). Becomes more evident that the early diagnosis of ovarian cancer will reduce the mortality.…”

Section: Discussionmentioning

confidence: 99%

Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival

Pradjatmo

2016

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival

Pradjatmo

2016

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

“…For example, unlike BRCA1 promoter methylation, BRCA2 promoter methylation is not associated with gene silencing in epithelial ovarian cancer. 171 , 172 Thus, analysis of BRCA2 promoter methylation will not yield useful information about DNA repair status of the cancer cells. If analysing methylation that is likely to be present at low levels (e.g.…”

Section: Methods For Measuring Dna Methylationmentioning

confidence: 99%

The role of aberrant DNA methylation in cancer initiation and clinical impacts

Geissler,

Nesic,

Kondrashova

et al. 2024

Ther Adv Med Oncol

View full text Add to dashboard Cite

Epigenetic alterations, including aberrant DNA methylation, are now recognized as bone fide hallmarks of cancer, which can contribute to cancer initiation, progression, therapy responses and therapy resistance. Methylation of gene promoters can have a range of impacts on cancer risk, clinical stratification and therapeutic outcomes. We provide several important examples of genes, which can be silenced or activated by promoter methylation and highlight their clinical implications. These include the mismatch DNA repair genes MLH1 and MSH2, homologous recombination DNA repair genes BRCA1 and RAD51C, the TERT oncogene and genes within the P15/P16/RB1/E2F tumour suppressor axis. We also discuss how these methylation changes might occur in the first place – whether in the context of the CpG island methylator phenotype or constitutional DNA methylation. The choice of assay used to measure methylation can have a significant impact on interpretation of methylation states, and some examples where this can influence clinical decision-making are presented. Aberrant DNA methylation patterns in circulating tumour DNA (ctDNA) are also showing great promise in the context of non-invasive cancer detection and monitoring using liquid biopsies; however, caution must be taken in interpreting these results in cases where constitutional methylation may be present. Thus, this review aims to provide researchers and clinicians with a comprehensive summary of this broad, but important subject, illustrating the potentials and pitfalls of assessing aberrant DNA methylation in cancer.

show abstract

“…The co-expression of DNA methyltransferase (DNMT)1 and 3a, DNMT1 and 3b, or DNMT3a and 3b contributes to the hypermethylation of the BRCA1 promoter, as previously described by Bai et al ( 43 ). Additionally, Pradjatmo ( 44 ) revealed that BRCA2 methylation was present in the majority of patients with OC, and that BRCA2 protein expression levels were associated with overall survival, regardless of the methylation status of BRCA2. This finding may guide the development of therapeutic approaches aimed at preventing or reversing BRCA gene methylation.…”

Section: Tumor Suppressor Genesmentioning

confidence: 99%

Current data and future perspectives on DNA methylation in ovarian cancer (Review)

Fu,

Deng,

Chen

et al. 2024

Int J Oncol

View full text Add to dashboard Cite

Ovarian cancer (OC) represents the most prevalent malignancy of the female reproductive system. Its distinguishing features include a high aggressiveness, substantial morbidity and mortality, and a lack of apparent symptoms, which collectively pose significant challenges for early detection. Given that aberrant DNA methylation events leading to altered gene expression are characteristic of numerous tumor types, there has been extensive research into epigenetic mechanisms, particularly DNA methylation, in human cancers. In the context of OC, DNA methylation is often associated with the regulation of critical genes, such as BRCA1/2 and Ras-association domain family 1A. Methylation modifications within the promoter regions of these genes not only contribute to the pathogenesis of OC, but also induce medication resistance and influence the prognosis of patients with OC. As such, a more in-depth understanding of DNA methylation underpinning carcinogenesis could potentially facilitate the development of more effective therapeutic approaches for this intricate disease. The present review focuses on classical tumor suppressor genes, oncogenes, signaling pathways and associated microRNAs in an aim to elucidate the influence of DNA methylation on the development and progression of OC. The advantages and limitations of employing DNA methylation in the diagnosis, treatment and prevention of OC are also discussed. On the whole, the present literature review indicates that the DNA methylation of specific genes could potentially serve as a prognostic biomarker for OC and a therapeutic target for personalized treatment strategies. Further investigations in this field may yield more efficacious diagnostic and therapeutic alternatives for patients with OC.

show abstract

Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia

Cited by 7 publications

References 22 publications

Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival

Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival

The role of aberrant DNA methylation in cancer initiation and clinical impacts

Current data and future perspectives on DNA methylation in ovarian cancer (Review)

Contact Info

Product

Resources

About